Meningococcal B vaccination strategies and their practical application in Italy


Meningococcal B vaccine


Immunisation against meningococcal meningitis has a long history, which has passed through several phases: the studies by Flexner, extraction of the polysaccharide capsule, the development of monovalent and multivalent conjugate vaccines, the outer membrane vesicle vaccines up to the development of effective and safe vaccines for meningococcal B invasive disease through the application of the techniques of molecular biology and reverse vaccinology.

The new available vaccines are Bexsero® and Trumenba®. Bexsero® has been approved and is available in Europe, the USA, Canada, Australia and Chile, and is currently under review in Brazil for the prevention of MenB invasive disease in subjects ≥ 2 months. Trumemba® is currently approved only in the USA, for use in adolescents and young adults.

At present, the greatest obstacle to the extensive use of these vaccines in industrialised countries is the high cost and the need administer multiple doses in infants. However, in some European countries and in some Italian Regions, strategies (free and active call) to fight the disease through vaccination (Bexsero) are already in place.


Snape MD, Pollard AJ. The beginning of the end for serogroup B meningococcus. Lancet 2013;381(9869):785-787. Available from: PubMed PMID: 23324564. doi: 10.1016/S0140-6736(12)62194-1. [Google Scholar]

Panatto D, Amicizia D, Lai PL, et al. New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers. Indian J Med Res 2013;138:835. [Google Scholar]

Gasparini R, Amicizia D, Lai PL, Panatto D. Neisseria meningitidis, pathogenetic mechanisms to overcome the human immune defences.. J Prev Med Hyg 2012;53(2):50-55. Available from: PubMed PMID: 23240160. [Google Scholar]

Notarangelo LD, Schumaker RF. Vaccinazione antimeningococcica. Area Pediatr 2003;4:38. [Google Scholar]

Bartolozzi G, Azzari C, Bona G, et al. Meningococco. Dalla vaccinazione d'emergenza alla prevenzione programmata. Milano: Medica Editoria e Diffusione Scientifica; 2011. [Google Scholar]

Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 2003;21(11-12):1094-1098. Available from: PubMed PMID: 12559785. doi: 10.1016/S0264-410X(02)00630-8. [Google Scholar]

Gasparini R, Rizzetto R, Sasso T, Rizzitelli E, Manfredi P, Risso D, et al. Seroprevalence of bactericidal antibody against Neisseria meningitidis serogroup C in pre-vaccinal era: the Italian epidemiological scenario.. Vaccine 2009 Feb;27(25-26):3435-3438. Available from: PubMed PMID: 19200821. doi: 10.1016/j.vaccine.2009.01.076. [Google Scholar]

Guzzetta G, Manfredi P, Gasparini R, Panatto D, Edmunds WJ. On the relationship between meningococcal transmission dynamics and disease: remarks on humoral immunity.. Vaccine 2009 Jan;27(25-26):3429-3434. Available from: PubMed PMID: 19460601. doi: 10.1016/j.vaccine.2009.01.092. [Google Scholar]

Gasparini R, Comanducci M, Amicizia D, Ansaldi F, Canepa P, Orsi A, et al. Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years.. J Clin Microbiol 2014 Mar;52(6):1901-1910. Available from: PubMed PMID: 24648565. doi:

1128/JCM.03584-13. [Google Scholar]

Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010;10(12):853-861. Available from: PubMed PMID: 21075057. doi: 10.1016/S1473-3099(10)70251-6. [Google Scholar]

Centers for Disease Control and Prevention , author. Active Bacterial Core Surveillance Report, Emerging Infections Program Network. Neisseria meningitidis, 1998-2009. Accessed June 19, 2015.

Surveillance of invasive bacterial diseases in Europe 2008/2009. Stockholm, Sweden: ECDC; 2011. European Centre for Disease Prevention and Control Surveillance Report.

Salud, P.d.l. (Organización) . Informe Regional de SIREVA II, 2009: Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae Neisseria meningitidis en procesos invasores. Washington, DC: Vigilancia Sanitaria, Prevención y Control de Enfermedades (HSD; 2010. [Google Scholar]

Takahashi H, Kuroki T, Watanabe Y, Tanaka H, Inouye H, Yamai S, et al. Characterization of Neisseria meningitidis isolates collected from 1974 to 2003 in Japan by multilocus sequence typing.. J Med Microbiol 2004;53(Pt 7):657-662. Available from: PubMed PMID: 15184538. doi: 10.1099/jmm.0.45541-0. [Google Scholar]

Australian Government – Department of Health. Immunise Australia Program. Meningococcal disease. Accessed June 19, 2015.

Dang V, Jamieson FB, Wilson S, et al. Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010. BMC Infect Dis 2012;29:12. [Google Scholar]

European Centre for Disease Prevention and Control , author . Surveillance of invasive bacterial diseases in Europe, 2012. Stockholm: ECDC; 2015. [Google Scholar]

Rota MC, Bella A, Angelo, F. D' , et al. Vaccinazione anti-meningococco B: Dati ed evidenze disponibili per l'introduzione in nuovi nati e adolescenti. Roma: Istituto Superiore di Sanità; 2015. [Google Scholar]

Azzari C, Canessa C, Lippi F, Moriondo M, Indolfi G, Nieddu F, et al. Distribution of invasive meningococcal B disease in Italian pediatric population: implications for vaccination timing.. Vaccine 2014;32(10):1187-1191. Available from: PubMed PMID: 24120548. doi: 10.1016/j.vaccine.2013.09.055. [Google Scholar]

Istituto Superiore di sanità – Sorveglianza MIB. La sorveglianza nazionale delle malattie invasive da meningococco, pneumococco ed emofilo e delle meningiti batteriche in Italia. Document available at: Accessed on 2015;19. [Google Scholar]

Resti M, Micheli A, Moriondo M, Becciolini L, Cortimiglia M, Canessa C, et al. Comparison of the effect of antibiotic treatment on the possibility of diagnosing invasive pneumococcal disease by culture or molecular methods: a prospective, observational study of children and adolescents with proven pneumococcal infection.. Clin Ther 2009;31(6):1266-1273. Available from: PubMed PMID: 19695393. doi: 10.1016/j.clinthera.2009.06.010. [Google Scholar]

Ladhani SN, Flood JS, Ramsay ME, Campbell H, Gray SJ, Kaczmarski EB, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines.. Vaccine 2012;30(24):3710-3716. Available from: PubMed PMID: 22429756. doi: 10.1016/j.vaccine.2012.03.011. [Google Scholar]

Flexner S. The results of serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 1913;17:533. [Google Scholar]

Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies.. J Exp Med 1969 Jun;129(6):1307-1326. Available from: PubMed PMID: 4977280. [Google Scholar]

Sophian A, Balck J. Prophylactic vaccination against epidemic meningitis. Jama 1912;59:527. [Google Scholar]

Greenwood M. The Outbreak of Cerebrospinal Fever at Salisbury in 1914-15.. Proc R Soc Med 1917;10(Sect Epidemiol State Med):44-60. Available from: PubMed PMID: 19979846. [Google Scholar]

Gates FL. A report on antimeningitis vaccination and observation on agglutinins in the blood of chronic meningococcus carriers. J Exp Med 1918;28:449. [Google Scholar]

Ferry NS. Active immunization with meningococcus toxin. Jama 1935;104:983. [Google Scholar]

Kuhns D, Kisner P, Williams MP, et al. The control of meningococcic meningitis epidemicsby active immunization with meningococcus soluble toxin: further studies. Jama 1938;110:484. [Google Scholar]

Gotschlich EC, Liu TY, Artenstein MS. Human immunity to meningococcus. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med 1969;129:1349. [Google Scholar]

Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to meningococcus. IV. Immungenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969;129:1367. [Google Scholar]

Gasparini R, Amicizia D, Domnich A, Lai PL, Panatto D. Neisseria meningitidis B vaccines: recent advances and possible immunization policies.. Expert Rev Vaccines 2014 Jan;13(3):345-364. Available from: PubMed PMID: 24476428. doi: 10.1586/14760584.2014.880341. [Google Scholar]

Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58.. Science 2000;287(5459):1809-1815. Available from: PubMed PMID: 10710307. doi: 10.1126/science.287.5459.1809. [Google Scholar]

Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development.. Vaccine 2001;19(17-19):2688-2691. Available from: PubMed PMID: 11257410. doi: 10.1016/S0264-410X(00)00554-5. [Google Scholar]

Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein.. Infect Immun 2004;72(4):2088-2100. Available from: PubMed PMID: 15039331. doi: 10.1128/IAI.72.4.2088-2100.2004. [Google Scholar]

Murphy E, Andrew L, Lee K, Dilts DA, Nunez L, Fink PS, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.. J Infect Dis 2009;200(3):379-389. Available from: PubMed PMID: 19534597. doi: 10.1086/600141. [Google Scholar]

Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010;28(9):2122-2129. Available from: PubMed PMID: 20044056. doi: 10.1016/j.vaccine.2009.12.027. [Google Scholar]

Mascioni A, Bentley BE, Camarda R, Dilts DA, Fink P, Gusarova V, et al. Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086. J Biol Chem 2008 Dec;284(13):8738-8746. Available from: PubMed PMID: 19103601. doi: 10.1074/jbc.M808831200. [Google Scholar]

Martinon-Torres F, Gimenez-Sanchez F, Bernaola-Iturbe E, Diez-Domingo J, Jiang Q, Perez JL. A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants. Vaccine 2014;32(40):5206-5211. Available from: PubMed PMID: 25077420. doi: 10.1016/j.vaccine.2014.07.049. [Google Scholar]

Kaaijk P, van Straaten I, van de Waterbeemd, (Bas) , Boot EPJ, Levels LMAR, van Dijken HH, et al. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine 2013;31(7):1065-1071. Available from: PubMed PMID: 23273968. doi: 10.1016/j.vaccine.2012.12.031. [Google Scholar]

Leca M, Bornet C, Montana M, Curti C, Vanelle P. Meningococcal vaccines: Current state and future outlook. Pathol Biol (Paris) 2015;63(3):144-151. Available from: PubMed PMID: 25986879. doi: 10.1016/j.patbio.2015.04.003. [Google Scholar]

Us . Food and Drug Administration. Trumenba. Avaialble at: Accessed on 2015;1. [Google Scholar]

Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.. Vaccine 2001 Oct;20 Suppl 1. Available from: PubMed PMID: 11587814. [Google Scholar]

Fine PEM, Mulholland k . Community immunity. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. fifth Edition. Elsevier; 2008. [Google Scholar]

Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.. Am J Epidemiol 2005 Jul;162(1):89-100. Available from: PubMed PMID: 15961591. doi: 10.1093/aje/kwi160. [Google Scholar]

Pan-Canadian Public Health Network. The Recommended Use of the Multicomponent Meningococcal B (4CMenB) Vaccine in Canada: Common Guidance Statement. Accessed on 1 July 2015.

Anderson RM, Nokes DJ. Mathematical models of transmission and control. In: Holland WW, Detels R, Knox G, editors. Oxford Textbook of Public Health. Second Edition. Oxford University Press, New York: Oxford Medical Publications; 1999. [Google Scholar]

Zoppi G, Trucchi C. Prevention of invasive diseases: strategies to increase vaccination coverage in children and adolescents.. J Prev Med Hyg 2012;53(2):125-129. Available from: PubMed PMID: 23240175. [Google Scholar]

Trotter CL, Maiden MCJ. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009;8(7):851-861. Available from: PubMed PMID: 19538112. doi: 10.1586/erv.09.48. [Google Scholar]

Maiden MCJ, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity. J Infect Dis 2008;197(5):737-743. Available from: PubMed PMID: 18271745. doi: 10.1086/527401. [Google Scholar]

WHO. Vaccine Introduction Guidelines Adding a vaccine to a national immunization programme: decision and implementation. guidelines_who_2005.pdf Accessed on 28 June 2015.

Gasparini R, Amicizia D, Lai PL, et al. Health Technology Assessment and vaccinations in Italy. GRHTA. 2014;1:16–24.

Gasparini R, Amicizia D, Lai PL, et al. Health Technology Assessment and vaccinations in Italy. GRHTA 2014;1:16. [Google Scholar]

Salute, d. (Ministero) . Piano Nazionale per la Prevenzione Vaccinale 2012-2014. pubblicazioni_1721_allegato.pdf. Accessed on 2015;1. [Google Scholar]

Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.. Vaccine 2013;31(23):2638-2646. Available from: PubMed PMID: 23566946. doi: 10.1016/j.vaccine.2013.03.034. [Google Scholar]

Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.. BMJ 2014 Oct;349. Available from: PubMed PMID: 25301037. [Google Scholar]

Capri S, Veneziano MA, Waure C. . 2013;13:68. [Google Scholar]

Regione Piemonte. ASL TO4. Vaccinazione pediatriche. Document available at: Accessed on 2 June, 2015.

Piemonte R. ASL TO4. Vaccinazione pediatriche. Document available at: Accessed on 2015;2. [Google Scholar]

Romagna RE. Aggiornamento delle indicazioni sulle vaccinazioni per la prevenzione delle Malattie invasive Batteriche nelle persone con patologie o condizioni di rischio. http: // Accessed on 2015;2. [Google Scholar]

Regione Puglia. Deliberazione n. 958 del 20-05-2014. Commissione Regionale Vaccini. Modifica Calendario Regionale per la vita 2012 – DGR 241/2013. Approvazione nuovo Calendario Vaccinale per la vita 2014. Available at: Accessed on June 29, 2015.

Regione Veneto. deliberazione della giunta regionale n. 1564 del 26 agosto 2014. Approvazione Nuovo "Calendario Vaccinale" della Regione del Veneto. Parziale modifica della D.G.R. n. 411 del 26.02.2008, approvazione documento "Offerta vaccinazioni soggetti a rischio", approvazione "Programma di formazione per gli operatori sanitari", approvazione documento "Piano di comunicazione a sostegno delle malattie infettive prevenibili con vaccino". Available at: Accessed on June 29, 2015.

Regione Friuli Venezia Giulia. Allegato alla Delibera n. 2535 del 18 dicembre 2014. Offerta Vaccinale regionale: infanzia e adolescenza. Avaialble at: 2014_2535/Allegato%201%20alla%20Delibera%202535-2014.pdf. Accessed on June 29, 2015.

Regione Toscana. Calendario vaccinale della Regione Toscana e direttive in materia di vaccinazioni. Aggiornamento al 2014. Available at: Accessed on June 29, 2015.

Regione Siciliana. Decreto assessorale 38/2015. Modifica e Integrazione del Calendario Vaccinale per la vita. Adottato con DA n° 0820/2012. Available at: Accessed on June 29, 2015.

Regione Liguria. Deliberazione della giunta regionale 22.12.2014 n. 1701 Piano Regionale Prevenzione Vaccinale, aggiornamento anno 2015. Bollettino Ufficiale Della Regione Liguria. Anno XLVI N. 3 del 21 gennaio 2015: 99-113. Available at: Accessed on June 29, 2015.

Provincia Autonoma di Bolzano. Dipartimento di Prevenzione. La vaccinazione protegge. Accessed on 2015;2. [Google Scholar]

Stefanelli P, Fazio C, Neri A, Boros S, Renna G, Pompa MG. Changing epidemiology of Infant Meningococcal Disease after the introduction of meningococcal serogroup C vaccine in Italy, 2006-2014.. Vaccine 2015;33(31):3678-3681. Available from: PubMed PMID: 26087297. doi: 10.1016/j.vaccine.2015.06.032. [Google Scholar]